US Stock MarketDetailed Quotes

RAPP Rapport Therapeutics

Watchlist
  • 10.120
  • +0.340+3.48%
Close Mar 20 16:00 ET
  • 10.120
  • 0.0000.00%
Post 16:20 ET
369.34MMarket Cap-4.73P/E (TTM)

Rapport Therapeutics Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Quarterly+Annual
YOY yoy
Hide blank lines yoy
(FY)Dec 31, 2024
(Q4)Dec 31, 2024
(Q3)Sep 30, 2024
(Q2)Jun 30, 2024
(Q1)Mar 31, 2024
(FY)Dec 31, 2023
(Q4)Dec 31, 2023
(Q3)Sep 30, 2023
(Q2)Jun 30, 2023
(Q1)Mar 31, 2023
Total revenue
0
0
0
0
0
0
0
0
0
0
Operating revenue
--0
--0
--0
--0
--0
--0
--0
--0
--0
--0
Cost of revenue
Gross profit
Operating expense
129.57%83.06M
58.99%23.52M
126.27%21.64M
213.73%20.8M
229.30%17.09M
36.18M
14.79M
9.56M
6.63M
5.19M
Selling and administrative expenses
170.42%22.12M
111.09%6.32M
207.31%6.1M
167.73%5.11M
255.26%4.59M
--8.18M
--3M
--1.98M
--1.91M
--1.29M
-General and administrative expense
170.42%22.12M
111.09%6.32M
207.31%6.1M
167.73%5.11M
255.26%4.59M
--8.18M
--3M
--1.98M
--1.91M
--1.29M
Research and development costs
117.63%60.94M
45.77%17.2M
105.05%15.54M
232.32%15.69M
220.70%12.5M
--28M
--11.8M
--7.58M
--4.72M
--3.9M
Operating profit
-129.57%-83.06M
-58.99%-23.52M
-126.27%-21.64M
-213.73%-20.8M
-229.30%-17.09M
-36.18M
-14.79M
-9.56M
-6.63M
-5.19M
Net non-operating interest income expense
380.33%12.14M
157.53%3.54M
379.32%4.1M
1,112.22%2.68M
2,320.00%1.82M
2.53M
1.38M
856K
221K
75K
Non-operating interest income
380.33%12.14M
157.53%3.54M
379.32%4.1M
1,112.22%2.68M
2,320.00%1.82M
--2.53M
--1.38M
--856K
--221K
--75K
Other net income (expense)
-557.47%-7.39M
0
-617.48%-7.39M
-1.12M
-94K
-1.03M
Other non- operating income (expenses)
-557.47%-7.39M
--0
----
----
-617.48%-7.39M
---1.12M
---94K
----
----
---1.03M
Income before tax
-125.18%-78.31M
-47.86%-19.98M
-101.39%-17.54M
-182.74%-18.12M
-268.84%-22.67M
-34.78M
-13.51M
-8.71M
-6.41M
-6.15M
Income tax
0
0
0
0
0
10K
6K
1K
2K
1K
Net income
-125.11%-78.31M
-47.79%-19.98M
-101.37%-17.54M
-182.65%-18.12M
-268.78%-22.67M
-34.79M
-13.52M
-8.71M
-6.41M
-6.15M
Net income continuous Operations
-125.11%-78.31M
-47.79%-19.98M
-101.37%-17.54M
-182.65%-18.12M
-268.78%-22.67M
---34.79M
---13.52M
---8.71M
---6.41M
---6.15M
Minority interest income
Net income attributable to the parent company
-125.11%-78.31M
-47.79%-19.98M
-101.37%-17.54M
-182.65%-18.12M
-268.78%-22.67M
-34.79M
-13.52M
-8.71M
-6.41M
-6.15M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders
-125.11%-78.31M
-47.79%-19.98M
-101.37%-17.54M
-182.65%-18.12M
-268.78%-22.67M
-34.79M
-13.52M
-8.71M
-6.41M
-6.15M
Basic earnings per share
83.64%-3.78
-49.16%-0.57
-38.90%-0.5
-541.54%-1.7
-269.97%-0.94
-23.1
-0.3821
-0.36
-0.265
-0.2541
Diluted earnings per share
83.64%-3.78
-49.16%-0.57
-38.90%-0.5
-541.54%-1.7
-269.97%-0.94
-23.1
-0.3821
-0.36
-0.265
-0.2541
Dividend per share
Currency Unit
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
Accounting Standards
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
Audit Opinions
Unqualified Opinion
--
--
--
--
Unqualified Opinion
--
--
--
--
(FY)Dec 31, 2024(Q4)Dec 31, 2024(Q3)Sep 30, 2024(Q2)Jun 30, 2024(Q1)Mar 31, 2024(FY)Dec 31, 2023(Q4)Dec 31, 2023(Q3)Sep 30, 2023(Q2)Jun 30, 2023(Q1)Mar 31, 2023
Total revenue 0000000000
Operating revenue --0--0--0--0--0--0--0--0--0--0
Cost of revenue
Gross profit
Operating expense 129.57%83.06M58.99%23.52M126.27%21.64M213.73%20.8M229.30%17.09M36.18M14.79M9.56M6.63M5.19M
Selling and administrative expenses 170.42%22.12M111.09%6.32M207.31%6.1M167.73%5.11M255.26%4.59M--8.18M--3M--1.98M--1.91M--1.29M
-General and administrative expense 170.42%22.12M111.09%6.32M207.31%6.1M167.73%5.11M255.26%4.59M--8.18M--3M--1.98M--1.91M--1.29M
Research and development costs 117.63%60.94M45.77%17.2M105.05%15.54M232.32%15.69M220.70%12.5M--28M--11.8M--7.58M--4.72M--3.9M
Operating profit -129.57%-83.06M-58.99%-23.52M-126.27%-21.64M-213.73%-20.8M-229.30%-17.09M-36.18M-14.79M-9.56M-6.63M-5.19M
Net non-operating interest income expense 380.33%12.14M157.53%3.54M379.32%4.1M1,112.22%2.68M2,320.00%1.82M2.53M1.38M856K221K75K
Non-operating interest income 380.33%12.14M157.53%3.54M379.32%4.1M1,112.22%2.68M2,320.00%1.82M--2.53M--1.38M--856K--221K--75K
Other net income (expense) -557.47%-7.39M0-617.48%-7.39M-1.12M-94K-1.03M
Other non- operating income (expenses) -557.47%-7.39M--0---------617.48%-7.39M---1.12M---94K-----------1.03M
Income before tax -125.18%-78.31M-47.86%-19.98M-101.39%-17.54M-182.74%-18.12M-268.84%-22.67M-34.78M-13.51M-8.71M-6.41M-6.15M
Income tax 0000010K6K1K2K1K
Net income -125.11%-78.31M-47.79%-19.98M-101.37%-17.54M-182.65%-18.12M-268.78%-22.67M-34.79M-13.52M-8.71M-6.41M-6.15M
Net income continuous Operations -125.11%-78.31M-47.79%-19.98M-101.37%-17.54M-182.65%-18.12M-268.78%-22.67M---34.79M---13.52M---8.71M---6.41M---6.15M
Minority interest income
Net income attributable to the parent company -125.11%-78.31M-47.79%-19.98M-101.37%-17.54M-182.65%-18.12M-268.78%-22.67M-34.79M-13.52M-8.71M-6.41M-6.15M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders -125.11%-78.31M-47.79%-19.98M-101.37%-17.54M-182.65%-18.12M-268.78%-22.67M-34.79M-13.52M-8.71M-6.41M-6.15M
Basic earnings per share 83.64%-3.78-49.16%-0.57-38.90%-0.5-541.54%-1.7-269.97%-0.94-23.1-0.3821-0.36-0.265-0.2541
Diluted earnings per share 83.64%-3.78-49.16%-0.57-38.90%-0.5-541.54%-1.7-269.97%-0.94-23.1-0.3821-0.36-0.265-0.2541
Dividend per share
Currency Unit USDUSDUSDUSDUSDUSDUSDUSDUSDUSD
Accounting Standards US-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions Unqualified Opinion--------Unqualified Opinion--------
Market Insights
Best Growth Stocks Best Growth Stocks

Spot stocks with huge growth potential and solid financial standing. Spot stocks with huge growth potential and solid financial standing.

Symbol Mini Chart % Chg
DexCom
DXCM
+2.36%
YETI Holdings
YETI
+1.26%
New Fortress Energy
NFE
+0.88%
Dorian LPG
LPG
+0.52%
Collegium Pharmaceutical
COLL
+0.27%

Unlock the Full List